Dergiler / Cerrahpaşa Medical Journal / 2022 / Cilt: 46 - Sayı: 1

Liver Transplantation for Congenital Metabolic Disorders

Sayfa
21–25
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Examining appropriate patient selection and ideal timing for transplantation remain important issues for further examination.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: The aim of the study is to identify the indications for and the outcomes of liver transplantation in congenital metabolic diseases.
📊
Temel Bulgular & Veri:Methods: Indications, survival, and complications of liver transplantation performed between July 2018 and September 2021 for congenital metabolic diseases were examined.
💡
Sonuç & Katkı:Examining appropriate patient selection and ideal timing for transplantation remain important issues for further examination.
🔬Tür:Araştırma Makalesi
📍Kapsam:2018 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: The aim of the study is to identify the indications for and the outcomes of liver transplantation in congenital metabolic diseases. Methods: Indications, survival, and complications of liver transplantation performed between July 2018 and September 2021 for congenital metabolic diseases were examined. Demographic information of patients, liver graft types, and donor information were included in the analysis. Results: A total of 23 liver transplants were performed in 22 patients with a mean age of 7.3 ± 9.3 and a mean weight of 23.6 ± 21.7. The types and frequencies of liver grafts used for transplantation in this analysis include 18 left lateral sectors, 1 left lobe, 3 right lobes, and 1 deceased full-size liver. Two of the left lateral sectors were retrieved from deceased split liver grafts. Mortality was observed in 2 patients (9%), 1 in the early and the second in the late postoperative period. Excluding the 2 fatalities, 3 patients required reoperation due to issues with blood flow through the portal vein. Due to hepatic artery thrombosis, 1 patient required stent placement. Biliary tract complications developed in 5 (22%) patients with dilatation and stenting being performed by interventional radiology. The surviving patients (91%) had an uneventful postoperative course after discharge from the hospital. Conclusion: Liver transplantation is increasingly used either as a definitive treatment method or to improve the course of the disease for metabolic diseases. With the high survival rates, reduction in the frequency of attacks, improved effects on growth, development, and nutrition, it is clear that liver transplantation is a valuable tool for use in congenital metabolic disorders. Examining appropriate patient selection and ideal timing for transplantation remain important issues for further examination.

🔖

Bu Makaleye Atıf Yap

KARATAŞ, C., KANMAZ, T., DEMİR, B., ALİM, A., TİRNOVA, İ., AKBULUT, A. (2022). Liver Transplantation for Congenital Metabolic Disorders. Cerrahpaşa Medical Journal, Cilt: 46 - Sayı: 1, 21–25. https://ajindex.com/articles/473093

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (3)

  1. Starzl TE, Marchioro TL, Vonkaulla KN, Hermann G, Brittain RS, Waddell WR. Homotransplantation of the liver in humans. Surg Gynecol Obstet. 1963;117:659-676
  2. Starzl TE, Iwatsuki S, Van Thiel DH, et al. Evolution of liver transplantation. Hepatology. 1982;2:614-636. [CrossRef] 3. Strong RW, Lynch SV, Ong TH, Matsunami H, Koido Y, Balderson GA. Successful liver transplantation from a living donor to her son. N Engl J Med. 1990;322:1505-1507. [CrossRef] 4. Pan ZY, Fan YC, Wang XQ, et al. Pediatric living donor liver transplantation decade progress in Shanghai: characteristics and risks factors of mortality. World J Gastroenterol. 2020;26(12):1352-1364. [CrossRef] 5. Mowat AP. Liver disorders in children: the indications for liver replacement in parenchymal and metabolic diseases. Transplant Proc. 1987;19(4):3236-3241
  3. Largillière C, Houssin D, Gottrand F, et al. Liver transplantation for ornithine transcarbamylase deficiency in a girl. J Pediatr. 1989;115(3):415-417. [CrossRef] 7. Menon J, Vij M, Sachan D, et al. Pediatric metabolic liver diseases: evolving role of liver transplantation. World J Transplant. 2021;11(6):161-179. [CrossRef] 8. Arnon R, Kerkar N, Davis MK, et al. Liver transplantation in children with metabolic diseases: the studies of pediatric liver transplantation experience. Pediatr Transplant. 2010;14(6):796-805. [CrossRef] 9. Wagenaar AE, Tashiro J, Sola JE, Ekwenna O, Tekin A, Perez EA. Pediatric liver transplantation: predictors of survival and resource utilization. Pediatr Surg Int. 2016;32(5):439-449. [CrossRef] 10. Shneider BL, Vockley J, Mazariegos GV. Trading places: liver transplantation as a treatment, not a cure, for metabolic liver disease. Liver Transpl. 2011;17(6):628-630. [CrossRef] 11. Ewing CB, Soltys KA, Strauss KA, et al. Metabolic control and “ideal” outcomes in liver transplantation for maple syrup urine disease. J Pediatr. 2021;237:59-64.e1. [CrossRef] 12. Siegel C, Arnon R, Florman S, Bucuvalas J, Oishi K. Nutritional management and biochemical outcomes during the immediate phase after liver transplant for methylmalonic acidemia. Nutrients. 2020;12(10):2976. [CrossRef] 13. Dal MB, Alim A, Acarli K. The advantage of early liver transplantation for Wilson's disease using living donors. Prz Gastroenterol. 2021;16(3):213-218. [CrossRef] 14. Khanna R, Verma SK. Pediatric hepatocellular carcinoma. World J Gastroenterol. 2018;24(35):3980-3999. [CrossRef] 15. Alim A, Dal MB, Erdoğan Y, et al. 1 ve canlı Vericil